 Nanobiotix NASDAQ: NBTX has announced a partnership with LianBio to develop and commercialize Nanobiotixs lead product candidate NBTXR3, in Greater China mainland China, Hong Kong, Taiwan, and Macau, South Korea, Singapore, and Thailand. NBTXR3 comprises functionalized hafnium oxide nanoparticles that are administered via one-time intratumoral injection and activated by radiotherapy. 